Zealand Pharma – Developing innovative peptide therapeutics

Share price information

ZEAL (COP)
417.10DKK

Last updated on 16 May 2025 17:09 (GMT +01:00)

Zealand Pharma is listed on Nasdaq Copenhagen under the ticker symbol ZEAL.
More Stock information
2024 Annual Report

Read Zealand Pharma's annual report for 2024
Download Report
Corporate presentation

See Zealand Pharma's latest Corporate Presentation from March 2025 for an overview of our R&D pipeline and additional company information.
Download PDF

PRESS RELEASE 12 May 2025

Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025
READ MORE
COMPANY ANNOUNCEMENT 09 May 2025

Zealand Pharma announces closing of collaboration and license agreement with Roche
READ MORE
COMPANY ANNOUNCEMENT 08 May 2025

Zealand Pharma Announces Financial Results for the First Three Months of 2025
READ MORE
PRESS RELEASE 01 May 2025

Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results
READ MORE

Obesity

As one of the greatest healthcare challenges of our time, obesity and overweight are associated with more than 220 complications and co-morbidities, including cardiovascular disease, liver disease, type 2 diabetes, kidney disease, and neuroinflammation. Zealand Pharma is working to address this chronic disease with differentiated product candidates.

Severely impacting quality of life, many rare diseases represent major unmet needs. Zealand Pharma has a long-standing commitment to people living with congenital hyperinsulinism (CHI) and short bowel syndrome (SBS).

Congenital hyperinsulinism Short Bowel Syndrome

Chronic inflammation

Through damage to tissues and organs, chronic inflammation can lead to the development of a broad range of potentially disabling or life-threatening illnesses. Zealand Pharma believes peptide medicines present opportunities for innovation in the treatment of chronic inflammatory diseases.

Obesity

Petrelintide

A long-acting amylin analog as a weight-loss medication representing an alternative to GLP-1 receptor agonists.

Obesity

Dapiglutide

A long-acting GLP-1/GLP-2 receptor dual agonist targeting obesity and low-grade inflammation.

Obesity

Survodutide

A long-acting glucagon/GLP-1 receptor dual agonist targeting obesity and MASH licensed to Boehringer Ingelheim.

Obesity

ZP6590

A GIP receptor agonist targeting obesity as a potential complement to GLP-1 for increased effect and/or tolerability.

Congenital Hyperinsulinism

Dasiglucagon: Continuous infusion

A glucagon analog designed to allow for continuous subcutaneous infusion via a wearable pump system for the treatment of Congenital Hyperinsulinism (CHI).

Short Bowel Syndrome

Glepaglutide

A long-acting GLP-2 analog designed to reduce or eliminate the need for parenteral support in SBS patients with intestinal failure.

Chronic inflammation

ZP9830

A potent and selective blocker of the Kv1.3 ion channel with the potential to treat a broad range of T-cell-driven autoimmune diseases.

Chronic inflammation

ZP10068

A long-acting inhibitor of the Complement C3 protein with the potential to target a broad range of complement-mediated diseases.

Safety, tolerability, and clinical effects of petrelintide (ZP8396), a long-acting amylin analog

Featured publication

Results from a 16-week Phase 1 multiple ascending dose (MAD) trial of petrelintide (ZP8396) presented at Obesity Week in November 2024.

Fostering an enriching workplace

At Zealand, we promote engagement, growth, diversity and inclusion. We believe that engaged and motivated employees with a passion for making a difference bring a positive mindset and inspiring level of energy to work. Our highly skilled employees are at the center of the medical treatment options that we design and develop for patients. We pride ourselves on our ability to work together as one team and to foster a strong and engaging company culture founded on collaboration, courage, empowerment, and trust.